Marker Therapeutics, Inc. (MRKR) · Nov 19, 2026 · Other events
$16.2M grant — Non-dilutive CPRIT award supporting planned Phase 2 APOLLO study
Marker Therapeutics won a $16.2M CPRIT grant to support MT-601’s planned Phase 2 lymphoma study, easing funding pressure but not proving efficacy.
Marker is a cash-constrained, clinical-stage immuno-oncology company trying to move MT-601 from encouraging Phase 1 lymphoma data into a planned Phase 2 study. Its latest 10-Q reported about $9.4 million of cash and a runway only into the second quarter of 2027 assuming no additional grant proceeds, while also flagging substantial doubt about continuing as a going concern.
The funding materially improves the near-term development story. CPRIT awarded Marker $16.2 million, more than the company held in cash at September 30, and designated the money for advancing MT-601 in the planned Phase 2 APOLLO study for patients with large B-cell lymphoma after CD19 CAR-T treatment. 〔0〕 This is meaningful because it can fund the central clinical program without immediately relying on another dilutive equity raise.
| Current figure | Comparison | ||
|---|---|---|---|
| CPRIT grant (Grant announcement) | $16.2M | Cash: $9.4M | |
| Phase 1 objective response rate (Clinical results) | 66% | 12 evaluable NHL patients | |
| Phase 1 complete response rate (Clinical results) | 50% | 12 evaluable NHL patients |
The grant validates the program’s fundability, not its clinical success. The award followed a competitive review that considered scientific merit, clinical strategy, regulatory issues, manufacturing, intellectual property and commercial potential, but it does not change MT-601’s status as an investigational therapy. The clinical evidence remains early: the cited response rates came from only 12 evaluable non-Hodgkin lymphoma patients, and the Phase 2 study is still described as planned.
The next proof point is still clinical execution. Marker says it expects to provide updated clinical results later in 2026. 〔1〕 Those data, rather than the grant itself, will determine whether the promising Phase 1 signal can support a larger development effort.
Bottom line: This is a clearly important financing and execution step: Marker has secured non-dilutive capital large enough to materially ease the funding burden around MT-601’s planned lymphoma Phase 2. It advances the business story, but leaves the core efficacy question unanswered until the next clinical update.
Updated MT-601 clinical results later in 2026
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!